Cellectar Biosciences, Inc. (CLRB) NASDAQ
2.97
-0.17(-5.41%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.97
-0.17(-5.41%)
Currency In USD
| Previous Close | 3.14 |
| Open | 3.11 |
| Day High | 3.13 |
| Day Low | 2.97 |
| 52-Week High | 20.7 |
| 52-Week Low | 2.43 |
| Volume | 146,060 |
| Average Volume | 1M |
| Market Cap | 9.48M |
| PE | -0.55 |
| EPS | -5.38 |
| Moving Average 50 Days | 2.93 |
| Moving Average 200 Days | 3.62 |
| Change | -0.17 |
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
GlobeNewswire Inc.
Feb 25, 2026 1:05 PM GMT
FLORHAM PARK, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that th
Cellectar Biosciences Expands Global Intellectual Property Estate
GlobeNewswire Inc.
Feb 17, 2026 1:05 PM GMT
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) f
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2026 1:05 PM GMT
Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe